Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Other Accumulated Expenses: 2017-2025

Historic Other Accumulated Expenses for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $2.7 million.

  • Aclaris Therapeutics' Other Accumulated Expenses rose 2.55% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 2.55%. This contributed to the annual value of $2.7 million for FY2024, which is 2.09% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Other Accumulated Expenses of $2.7 million as of Q3 2025, which was up 0.66% from $2.7 million recorded in Q2 2025.
  • Aclaris Therapeutics' Other Accumulated Expenses' 5-year high stood at $2.7 million during Q3 2025, with a 5-year trough of $217,000 in Q4 2022.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $2.7 million (2024), whereas its average is $2.1 million.
  • In the last 5 years, Aclaris Therapeutics' Other Accumulated Expenses plummeted by 87.49% in 2022 and then spiked by 1,111.06% in 2023.
  • Over the past 5 years, Aclaris Therapeutics' Other Accumulated Expenses (Quarterly) stood at $1.7 million in 2021, then plummeted by 87.49% to $217,000 in 2022, then skyrocketed by 1,111.06% to $2.6 million in 2023, then grew by 2.09% to $2.7 million in 2024, then climbed by 2.55% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.7 million for Q2 2025, and $2.7 million during Q1 2025.